Skip to content
type1.science
Phase 2/3RecruitingNCT07284511

Tirzepatide with Control-IQ to reduce meal announcements

McGill-led phase 2/3 trial testing whether weekly tirzepatide can help adults using Tandem Control-IQ reduce or eliminate carbohydrate counting and meal announcements while preserving daytime time-in-range.

Primary endpoints

  • Daytime time-in-range during the final 6 weeks of the study

Results so far

No results posted yet.